Document:

Exhibit
10.34

 

**Confidential
portions have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities
and Exchange Commission (the “Commission”)**

 

General
Technical Agreement

 

This
General Technical Agreement (this “Agreement”) is entered into as of July 24, 2016 (the “Effective
Date”) by and between Oramed Ltd., a company organized under the laws of the State of Israel, with its offices
at 2/4 Kefar Hi-tech, PO Box 39098, Jerusalem, 91390, Israel, and with the following facsimile number +972-2-566-0004 and email
address josh@oramed.com (“Oramed”), and PREMAS Biotech Pvt. Ltd, a company organized under the laws
of India, with its offices at Plot 77, Sector 4, IMT Manesar, Gurgaon 122050, Haryana, India, and with an email address prabuddha.kundu@premasbiotech.com
(“Premas”).

 

Whereas,
Oramed controls rights covering the compound known as ORMD-0801;

 

Whereas,
Oramed and Premas entered into manufacturing agreements dated July 2013, May, 2014 and December, 2014 amongst others (the “Manufacturing
Agreements”) pursuant to which Premas was designated as a contract manufacturer for the production and supply of Soybean
Trypsin Inhibitor/SBTI (the “Product”);

 

Whereas,
Oramed entered into a Technology License Agreement (“License Agreement”) with Hefei Tianhui Incubator of Technologies
Co., Ltd. (“HTIT”), a corporation organized and existing under the laws of the People’s Republic of China
(the “PRC”) pursuant to which, inter alia, Oramed granted HTIT exclusive rights to pre-commercialize,
manufacture and commercialize the Products (including the oral insulin soft gelatin capsule and SBTI that is needed for making
this capsule product) in the PRC, Macau and Hong Kong (the “Licensee Territory”);

 

Whereas,
as part of the License Agreement, Oramed undertook to provide technical information to enable HTIT to manufacture the SBTI in
the Licensee Territory (the “Purpose”); and

 

Whereas,
Oramed has requested Premas, and Premas has agreed to transfer such information to Oramed and to collaborate with Oramed to ensure
the transfer to HTIT of such information, all in accordance with the terms and conditions set out in this Agreement;

 

Now,
therefore, in consideration of the mutual covenants and conditions set forth herein, the parties agree as follows:

 

	1.	The
                                         Services. Premas hereby agrees to collaborate with Oramed and develop the scalable
                                         process for production of SBTI at [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT
                                         TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]
                                         kgs/week (while maintaining the same quality and characteristics of the SBTI currently
                                         manufactured by Premas pursuant to the Manufacturing Agreements). In this respect, Premas
                                         will transfer to Oramed that technical information set out in Annex 1 hereto (the
                                         “Technical Information”) as well as Premas’ developed production
                                         process to produce [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST
                                         FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] batches
                                         of SBTI at each batch size of [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT
                                         TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION]
                                         kg per week at HTIT’s facility in the Licensee Territory (and Oramed will thereafter
                                         make same available to HTIT in accordance with Oramed’s undertakings to HTIT in
                                         the License Agreement as noted below in Section 3.2). Premas will have the option to
                                         additionally make best efforts to develop and transfer a process to produce [THE CONFIDENTIAL
                                         PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS
                                         BEEN FILED SEPARATELY WITH THE COMMISSION] kg per week at HTIT’s facility in
                                         the Licensee Territory upon discussions with Oramed which will be covered under a separate
                                         agreement It is hereby clarified and agreed that while it is HTIT’s responsibility
                                         to design, build and commission such manufacturing facilities of various scales, Premas
                                         will make best efforts to transfer and guide said development, especially regarding the
                                         space layout, equipments specifications, process (flow and parameters), utilties, commissioning,
                                         operational procedures, qualifications and validations, raw materials selection and specifications
                                         (including the analytical methods and instruments), analytical methods (including the
                                         instrument requirement) for in-process controls, intermediates, and final products, and
                                         related documents. Such collaboration and assistance by Premas shall hereinafter be referred
                                         to as the “Services”. For clarity, it is Premas’ responsibilities
                                         (1) to transfer the SBTI manufacturing process and technology at batch size of [THE
                                         CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT
                                         AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] kg per week to HTIT, (2) to guide
                                         HTIT to design and construct and validate the SBTI manufacturing facility at batch size
                                         of [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
                                         TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] kg per week, (3) to
                                         achieve [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
                                         TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] batches of SBTI at each
                                         batch size of [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST
                                         FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] kg
                                         per week at HTIT’s facility after maximum [THE CONFIDENTIAL PORTION HAS BEEN
                                         SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY
                                         WITH THE COMMISSION] at the same facility, (4) to prepare and provide HTIT all the
                                         technical documents (like drawings, specifications, operatioan procedures, protocols
                                         for qualifications and validations, etc.) related to the manufacturing process and quality
                                         controls and train HTIT staff so that HTIT’s facility can be run under GMP conditions,
                                         and (5) to generate, prepare and provide HTIT all the technical information set out in
                                         Annex 1. Premas shall provide the Services in coordination with Oramed, and in
                                         a professional, competent and timely manner. 

 

     

     

    

 

	2.	Compensation

 

	2.1.	Oramed will pay Premas for the Services as per the budget
set out in Annex 2 (the “Budget”) following the successful completion of each of the tasks listed therein.
Such amounts will be due and payable 30 days after the date of each respective invoice from Premas, supported by copies of applicable
receipts and details, approved by Oramed. Aside from payment as aforesaid, Premas shall not be entitled to any other compensation
or reimbursement under this Agreement.

 

	2.2.	Premas will use best efforts to procure, in accordance
with the Budget, the necessary equipment, consumables and raw material to develop the scale-up process to successfully produce
at least [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED
SEPARATELY WITH THE COMMISSION] kg/week of SBTI. However, in the event that Premas, after using best efforts, is unable to
meet the production deliverables (that is, the successful production of at least [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED
PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE COMMISSION] kg per week of SBTI as
aforesaid), Premas will arrange for the sale of the procured equipment, unused consumables and raw material on arms-length terms,
and will use best efforts to recover as much as possible, and transfer to Oramed all the proceeds from the sale, it being agree
that any such sale shall be subject to Oramed’s prior written approval. In the event, that Premas is successful in delivering
the agreed production deliverables, the sale mechanism in this clause will become void, and Premas will only utilize the aforesaid
equipment, unused consumables and unused raw material, to produce any subsequent Oramed orders of SBTI. In no event may Premas
transfer, sell or place any encumbrance on any such equipment, unused consumables or unused raw material. 

 

	3.	Confidentiality
                                         and Intellectual Property. 

 

	3.1.	Oramed shall ensure that HTIT is bound by appropriate
non-disclosure and non-use provisions with respect to the use of the Technical Information. As between Premas and Oramed, Premas
shall be subject to the confidentiality provisions of the Manufacturing Agreements with respect to the Technical Information.

 

	3.2.	Premas hereby transfers and assigns to Oramed (and undertakes
to do transfer and assign to Oramed upon creation) all right, title and interest in and to the Technical Information and all intellectual
property rights subsisting in and/or related to the Technical Information such that Oramed shall become the exclusive legal owner
thereof with the unrestricted right to exploit same on a worldwide basis without further accounting to Premas. Oramed, for its
part, hereby agrees to grant HTIT rights in the foregoing Technical Information and intellectual property rights to support the
efforts of HTIT to build up the SBTI manufacturing facilities and to produce the SBTI product in China, as per the terms of the
License Agreement. 

 

    	 	2	 

     

    

 

	3.3.	Premas hereby represents and warrants that the Technical
Information, intellectual property rights subsisting therein and related thereto, and its Services under this Agreement do not
and will not infringe any intellectual property rights from any third party. 

 

	4.	Cooperation.
                                         Premas will cooperate with Oramed and, to the extent requested by Oramed, its agents,
                                         subcontractors and partners (including without limitation HTIT) to facilitate the efficient
                                         transfer of information hereunder. Premas will provide to Oramed and, to the extent requested
                                         by Oramed, its agents, subcontractors and partners (including without limitation HTIT),
                                         and their auditors, inspectors, regulators and other representatives, access at all reasonable
                                         times (and in the case of regulators at any time required by such regulators) to any
                                         facility of Premas, and to data and records relating to the Manufacturing Agreement to
                                         verify the integrity of the Technical Information and the process of transferring information
                                         hereunder. In addition, Premas will take all further necessary and reasonable actions
                                         as may be required by Oramed to give effect to the arrangements contemplated in Section
                                         3.2 above, including following any termination or expiration of this Agreement.

 

	5.	Term and Termination.

 

	5.1.	This Agreement will commence on the Effective Date and
will remain in effect until the successful completion of the transfer of the Technical Information and the completion of the provision
of the Services as contemplated in this Agreement.

 

	5.2.	Oramed alone shall have the right to terminate the provision
of Services and this Agreement at any time without cause upon 15 days’ prior written notice to Premas. Either party may
terminate this Agreement at any time upon 45 days’ prior written notice to the other party, for any breach of this Agreement
by the other party where such breach is not remedied to the non-breaching party’s reasonable satisfaction within a 30 day
notice period. Additionally, either party may terminate this Agreement, upon written notice taking immediate effect, upon the
filing by any person of a petition for the winding-up or liquidation or the appointment of a receiver on most of the assets of
the terminated party, if petition has not been withdrawn or dismissed within 30 days of its filing.

 

	5.3.	Upon expiration or earlier termination hereof, neither
party will have any further obligations under this Agreement, except that (i) the liabilities (contractual, financial and statutory)
accrued before the effective date of expiration or termination and (ii) the obligations which by their nature survive termination,
including the confidentiality and intellectual property provisions of this Agreement, shall survive termination.

 

	5.4.	Both parties agree that since this Agreement involves
an interested third party, they will exercise the abovementioned termination rights in a reasonable manner.

 

	6.	Liablity
                                         of Breach Contract Either party breach this agreement or fail to fulfill its obligations
                                         under this agreement, it shall take the liability for breach of contract and indemnify
                                         for losses thus incurred to the other party limited to the value of the part of the contract,
                                         ie. TT part or the part involved there of. . If such breach cause the loss of third party,
                                         joint responsibility shall be taken by both parties and non-defaulter has the right of
                                         recovery, however, limited to the value of the part of the contract involved, ie. TT
                                         part.or there of .

 

	7.	Miscellaneous.

 

	7.1.	Notices. Any notice required or permitted to
be given under this Agreement shall be in writing, shall specifically refer to this Agreement, and shall be addressed to the appropriate
party at the address set out above or such other address as may be specified by such party in writing in accordance with this
section, and shall be deemed to have been sufficiently given for all purposes when received, if in writing and personally delivered,
one (1) day following facsimile or email transmission (receipt verified) or two (2) days following overnight express courier service
(signature required), prepaid, to the party for which such notice is intended, at the address set forth for such party above.

 

    	 	3	 

     

    

 

	7.2.	Independent Contractors. The parties are independent
contractors; Premas shall not be considered or deemed to be an agent, employee, joint venture or partner of Oramed. Neither party
has any authority to contract for or bind the other party in any manner.

 

	7.3.	Assignment. This Agreement, and the rights and
obligations hereunder, may not be assigned or transferred by either party without the prior written consent of the other party,
which consent will not be unreasonably withheld, except that either party may assign this Agreement to an affiliate or to a successor
to its business (whether by merger, a sale of all or substantially all of its assets relating to this Agreement, a sale of a controlling
interest of its capital stock, or otherwise) which agrees in writing to assume its obligations hereunder; in such event, prompt
notice shall be given to the other party.

 

	7.4.	Entire Agreement. This Agreement, together with
any exhibit(s), constitutes the entire agreement of the parties, superseding any and all previous agreements and understandings,
whether oral or written, as to the same subject matter. No modification or waiver of the provisions of this Agreement shall be
valid or binding on either party unless in writing and signed by both parties. No waiver of any term, right or condition under
this Agreement on any occasion shall be construed or deemed to be a waiver or continuing waiver of any such term, right or condition
on any subsequent occasion or a waiver of any other term, right or condition hereunder. This Agreement shall be binding upon and
inure to the benefit of the parties and their permitted successors and assigns.

 

	7.5.	Severability. If any one or more of the provisions
contained in this Agreement will, for any reason, be held to be invalid, illegal or unenforceable in any respect, that invalidity,
illegality or unenforceability will not affect any other provisions of this Agreement, and all other provisions will remain in
full force and effect. In such event, the parties shall use their good faith efforts to replace the invalid, illegal or unenforceable
provision with a valid, legal or enforceable provision, which shall approximate as closely as possible the purpose of the invalid,
illegal or unenforceable provision.

 

	7.6.	Applicable Law. This Agreement shall be governed
by and construed under the laws of the State of Israel without giving effect to rules of conflict of laws and the parties hereto
voluntarily, unconditionally and irrevocably submit to the sole and exclusive jurisdiction of the appropriate courts of competent
jurisdiction of Jerusalem to the absolute exclusion of any other court and any other jurisdiction.

 

    	 	4	 

     

    

 

IN
WITNESS WHEREOF, the parties have duly executed this Agreement by their authorized representatives as of the date first set forth
above.

 

	Oramed
    Ltd.	 	Premas
	 	 	 
	/s/
    Nadav Kidron	 	By:	/s/
    Prabuddha k Kundu
	Nadav
    Kidron	 	Name:	Prabuddha
    k Kundu
	Chief
    Executive Officer	 	Title:	Executive
    Director 

 

/s/
Harold Jacob

 

Harold
Jacob

 

Director
Oramed Pharmaceuticals Inc.

 

    	 	5	 

     

    

 

Annex
1

 

[THE
CONFIDENTIAL PORTIONS HAVE BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAVE BEEN FILED SEPARATELY WITH
THE COMMISSION]

 

 

 

 

 

 

 

 

    	 	6	 

     

    

 

ANNEX
2: Cash Flow and Invoicing details

 

	 	 	 	 	 	(USD,
    $, 000)	 	 	 	 	 	 
	 	1	2	3	4	5	6	7	8	9	10	11	 
	Cash
    Inputs	Jul-16	Aug-16	Sep-16	Oct-16	Nov-16	Dec-16	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Total
    (US $)
	Infrastructural
    Development, CAPEX, etc	800	300	400	 	 	 	 	 	 	 	 	1500
	Scale
    Up	 	 	 	 	100	100	 	 	 	 	 	200
	Raw
    Material	75	50	100	100	 	50	100	25	 	 	 	500
	Production	 	 	 	70	70	160	160	160	 	160	320	1100
	GMP
    Analytics	 	 	 	 	100	100	100	 	 	 	300	600
	Misc	 	 	 	 	50	 	 	 	50	 	 	100
	Tech
    Transfer 	 	 	 	 	20	20	20	20	20	 	200	300
	Total	875	350	500	170	340	430	380	205	70	160	820	4300
	 	CAPEX,
    RM, Infrastruture	Scale
    up to [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY
    WITH THE COMMISSION] kg/week	Production
    of [THE CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY
    WITH THE COMMISSION] kgs per month SBTI	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 
	Cash
    Inputs (Month wise)	2016
    - 2017 ($ USD, ’000)
	 	Jul-16	Aug-16	Sep-16	Oct-16	Nov-16	Dec-16	Jan-17	Feb-17	Mar-17	Apr-17	May-17	Total
    (US $)
	 	875	350	500	170	340	430	380	205	70	160	820	4300
	 	 	 	 	 	 	 	 	 	 	 	 	 

Total
project pricing

 

USD
$ Four million, three hundred thousand only as given in the cash flow as above.

 

    	 	7	 

     

    

 

[THE
CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH THE
COMMISSION]

 

General
(not limited) responsibilities of the parties:

 

	No.	Work/Activities	Responsible
    Party(ies)	Supporting/Involved
    Party(ies)
	1	[THE
    CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH
    THE COMMISSION]	Oramed/Premas	with
    HTIT involved/informed; HTIT is to review the process and development package.
	2	[THE
    CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH
    THE COMMISSION]	Oramed/Premas	with
    HTIT involved/informed; HTIT is to review the TTP.
	2	[THE
    CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH
    THE COMMISSION]	Oramed/Premas	with
    HTIT involved/informed
	3	[THE
    CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH
    THE COMMISSION]	Oramed/Premas	with
    HTIT involved/informed
	4	[THE
    CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH
    THE COMMISSION]	HTIT,
    based on the above info provided by Oramed/Premas;	Oramed/Premas
    to plan, support and review the URS
	5	[THE
    CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH
    THE COMMISSION]	Oramed/Premas	 
	6	[THE
    CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH
    THE COMMISSION]	HTIT,
    based on the above info provided by Oramed/Premas;	Oramed/Premas
    need to review the civil design to make sure it meets the requirements of manufacture process.

 

    	 	8	 

     

    

 

	7	[THE
    CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH
    THE COMMISSION]	HTIT	Oramed/Premas
    to review
	8	[THE
    CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH
    THE COMMISSION]	Oramed/Premas	with
    HTIT involved
	9	[THE
    CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH
    THE COMMISSION]	HTIT	Technically
    supported by Oramed/Premas
	10	[THE
    CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH
    THE COMMISSION]	HTIT	Oramed/Premas
    to support and review
	11	[THE
    CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH
    THE COMMISSION]	Oramed/Premas	to
    be approved by HTIT QA
	12	[THE
    CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH
    THE COMMISSION]	HTIT	Technically
    supported by Oramed/Premas
	13	[THE
    CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH
    THE COMMISSION]	HTIT	Oramed/Premas
    to support and review
	14	[THE
    CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH
    THE COMMISSION]	HTIT	Oramed/Premas
    to support and review
	15	[THE
    CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH
    THE COMMISSION]	Oramed/Premas	to
    be reviewed and approved by HTIT QA

 

    	 	9	 

     

    

 

	16	[THE
    CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH
    THE COMMISSION]	Oramed/Premas	 
	17	[THE
    CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH
    THE COMMISSION]	Oramed/Premas	to
    be implemented by HTIT people or supplier under guide and supervision of Oramed/Premas; responsibility is on Oramed/Premas.
	18	[THE
    CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH
    THE COMMISSION]	Oramed/Premas	to
    be implemented by HTIT people under guide and supervision of Oramed/Premas
	19	[THE
    CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH
    THE COMMISSION]	Oramed/Premas	to
    be approved by HTIT QA
	20	[THE
    CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH
    THE COMMISSION]	Oramed/Premas	to
    be implemented by HTIT people under guide and supervision of Oramed/Premas; responsibility is on Oramed/Premas
	21	[THE
    CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH
    THE COMMISSION]	Methods:
        Oramed/Premas;

        Execution:
        HTIT under guide and supervision of Oramed/Premas;
	responsibility
    is on Oramed/Premas before the successful PV batches achieved.
	22	[THE
    CONFIDENTIAL PORTION HAS BEEN SO OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND HAS BEEN FILED SEPARATELY WITH
    THE COMMISSION]	Oramed/Premas	HTIT
    to assist the arangements

 

 

10addentax_ex101.htm

EXHIBIT 10.1
 
ACTION BY WRITTEN CONSENT OF DIRECTORS
 
(Nevada Revised Statutes 78.315(2))
 
OF
 
ADDENTAX GROUP CORP.
 
A Nevada Corporation
 
The undersigned, Sole Director of ADDENTAX GROUP CORP., a Nevada Corporation (the "Corporation") pursuant to the Bylaws of the Corporation and the Nevada Revised Statutes, hereby consents to the following actions of the Corporation as of November 21, 2016. 
 
	1.

	APPOINTMENT OF OFFICERS AND DIRECTORS

 
RESOLVED: That the Board of Directors hereby accepts the Resignation Letter submitted by Otmane Tajmouati from the offices of President, Chief Executive Officer, Chief Financial Officer, Chairman, Secretary, Treasurer, and Director effective November 21, 2016.
 
RESOLVED: That the following individual was appointed to serve in all officer and/or director positions:
 
		Yu Keying
	CEO, President, Secretary, Treasurer, CFO, Director, Chairman

 
	2.	OMNIBUS RESOLUTION

 
RESOLVED FURTHER, that the foregoing officer of the Corporation, and such persons appointed to act on his behalf pursuant to the foregoing resolutions, are hereby authorized and directed in the name of the Corporation and on its behalf, to execute any additional certificates (including any officer's certificates), agreements, instruments or documents, or any amendments or supplements thereto, or to do or to cause to be done any and all other acts as they shall deem necessary, appropriate or in furtherance of the full effectuation of the purposes of each of the foregoing resolutions.
 
This Unanimous Written Consent of the Board of Directors of ADDENTAX GROUP CORP. may be executed in any number of counterparts and each of such counterparts shall for all purposes constitute one Written Consent, notwithstanding that all directors are not signatories to the same counterpart, effective as of the date first written above. This Unanimous Written Consent may be executed by facsimile and such facsimile copy shall be conclusive evidence of the consent and ratification of the matters contained herein by the undersigned director.
 
Dated: November 25, 2016
 
/s/ Otmane Tajmouati                                   
Otmane Tajmouati, Director

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}]]